ERBB2 and breast carcinoma: Currently, alpelisib is being evaluated in combination with fulvestrant in patients with HR-positive, HER2-negative advanced breast cancer after treatment with CDK4/6 inhibitors and AI in phase III EPIK-B5 trial (NCT05038735).